Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.
Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.
复制标题
使用利鲁唑治疗重度抑郁症后出现迟发性遗忘综合征：病例报告。
DOI：
10.1016/j.psym.2013.02.002
复制
发表时间：
2013
期刊：
影响因子：
3.4
通讯作者：
Mischoulon,David
中科院分区：
文献类型：
--
作者：
Cardoos,Amber;Inamori,Aya;Sanacora,Gerard;Fava,Maurizio;Mischoulon,David
难治性抑郁症（TRD）仍然是一个常见的问题，29-46%的抑郁症患者对抗抑郁药物的充分试验没有足够的反应。1最近，美国食品药品监督管理局（FDA）批准用于治疗肌萎缩侧索硬化症（ALS）的抗抑郁药利鲁唑的几项开放标签临床试验显示，其对重度抑郁症、广泛性焦虑症和强迫症患者具有抗抑郁作用。2-5利鲁唑（剂量为100 mg/天）最常见的副作用包括虚弱（19.2%）、恶心（16.3%）和肺功能下降（10.2%）;其他常见但不太常见（< 10%）的副作用包括头晕、腹泻、腹痛、呕吐、眩晕、口腔感觉异常、厌食、失眠、嗜睡和精神症状，如抑郁6。更严重和罕见的不良反应，健忘症，以前曾报告过两次，在过量的情况下。在第一个病例中，一名患有亨廷顿舞蹈症的妇女在服用3克利鲁唑后4天出现了持续一年多的延迟性遗忘症。7在第二个病例中，一名患有亨廷顿氏病的妇女在服用2.8 g利鲁唑4天后出现严重的遗忘综合征，伴有顺行性和逆行性遗忘以及注意力和短期记忆缺陷。在后一种情况下，患者的认知功能逐渐改善，并在中毒后一年内恢复到基线水平。我们在这里报告的情况下，全球健忘症有关的指导使用利鲁唑在随机临床试验（RCT）的设置。
Treatment-resistant depression (TRD) remains a common problem, with 29–46% of depressed patients failing to respond sufficiently to adequate trials of antidepressant medications. 1 Recently, several open-label clinical trials of riluzole, an antiglutamatergic drug approved by the US Food and Drug Administration (FDA) for treatment of amytrophic lateral sclerosis (ALS), have revealed antidepressant effects in individuals with major depressive disorder, generalized anxiety disorder, and obsessive-compulsive disorder. 2–5The most common side effects of riluzole (at doses of 100mg/day) include asthenia (19.2%), nausea (16.3%), and decreased lung function (10.2%); other common but less frequent (< 10%) side effects include dizziness, diarrhea, abdominal pain, vomiting, vertigo, oral parasthesia, anorexia, insomnia, somnolence, and psychiatric symptoms such as depression6. A more serious and rare adverse effect, amnesic syndrome, has been previously reported twice, in the context of overdose. In the first case, a woman with Huntington’s disease developed delayed amnesia that persisted for over a year, four days after ingesting 3g of riluzole. 7 In the second case, a woman with Huntington’s disease developed severe amnesic syndrome with anterograde and retrograde amnesia as well as attention and short-term memory deficits, four days after ingesting 2.8 g of riluzole. 8 In the latter case, the patient’s cognitive functions improved gradually and returned to baseline within a year of the intoxication8. We report here a case of global amnesia related to as-directed use of riluzole in the setting of a randomized clinical trial (RCT).